Distribution of Traditional and Novel Risk Factors and Their Relation to Subsequent Cardiovascular Events in Patients With Acute Coronary Syndromes (from the PROVE IT-TIMI 22 Trial)

American Journal of Cardiology

Volumn 105, Issue 5, 2010, Pages 619-623

  Acharjee, Subroto ^a   Qin, Jie ^b   Murphy, Sabina A ^b   McCabe, Carolyn ^b   Cannon, Christopher P ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; GATIFLOXACIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; PRIORITY JOURNAL; STROKE; SYSTOLIC BLOOD PRESSURE; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; CHOLESTEROL; COHORT STUDIES; FEMALE; HEPTANOIC ACIDS; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PRAVASTATIN; PYRROLES; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 77149140110     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.10.042     Document Type: Article

References (23)

1. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., and Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
2. Khot U.N., Khot M.B., Bajzer C.T., Sapp S.K., Ohman E.M., Brener S.J., Ellis S.G., Lincoff A.M., and Topol E.J. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 290 (2003) 898-904
3. Greenland P., Knoll M.D., Stamler J., Neaton J.D., Dyer A.R., Garside D.B., and Wilson P.W. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 290 (2003) 891-897
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
5. Hokanson J.E., and Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of HDL cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3 (1996) 213-219
6. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., McQueen M., Budaj A., Pais P., Varigos J., Lisheng L., and INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004) 937-952
7. Balkau B., Shipley M., Jarrett R.J., Pyörälä K., Pyörälä M., Forhan A., and Eschwège E. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-Year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 21 (1998) 360-367
8. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
9. Pai J.K., Pischon T., Ma J., Manson J.E., Hankinson S.E., Joshipura K., Curhan G.C., Rifai N., Cannuscio C.C., Stampfer M.J., and Rimm E.B. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351 (2004) 2599-2610
10. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., and Skene A.M.P.o.A.E.T.-T.i.M.I.22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
11. Yusuf S., Pais P., Afzal R., Xavier D., Teo K., Eikelboom J., Sigamani A., Mohan V., Gupta R., Thomas N., and Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 373 (2009) 1341-1351
12. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
13. Pedersen T.R., Kjekshus J., Berg K., Haghfelt T., Faergeman O., Faergeman G., Pyörälä K., Miettinen T., Wilhelmsen L., Olsson A.G., Wedel H., and Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
14. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., and Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 335 (1996) 1001-1009
15. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., and Gotto Jr. A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
16. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
17. Collins R., Armitage J., Parish S., Sleigh P., Peto R., and Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo controlled trial. Lancet 361 (2003) 2005-2016
18. Deedwania P., Barter P., Carmena R., Fruchart J.C., Grundy S.M., Haffner S., Kastelein J.J., LaRosa J.C., Schachner H., Shepherd J., Waters D.D., and Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 368 (2006) 919-928
19. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., Pfeffer M.A., Braunwald E., and Pravastatin or Atorvastatin and Evaluation Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
20. Morrow D.A., de Lemos J.A., Sabatine M.S., Wiviott S.D., Blazing M.A., Shui A., Rifai N., Califf R.M., and Braunwald E. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 114 (2006) 281-288
21. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto Jr. A.M., Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., Macfadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., Glynn R.J., and JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373 (2009) 1175-1182
22. Ridker P.M., Buring J.E., Rifai N., and Cook N.R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297 (2007) 611-619
23. Ridker P.M., Paynter N.P., Rifai N., Gaziano J.M., and Cook N.R. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 118 (2008) 2243-2251